Skip to main content

Table 1 Clinical characteristics of the patients with de novo Ph+ALL for in vitro and in vivo study

From: Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL

Case no.

Age/sex

WBC (×10E + 9/L)

% CD34+ in blasts

% CD34+CD38− CD58− in blasts

BCR–ABL (P190/P210)

Cytogenetics

Outcome

1

F/23

26.3

90.5

5.6

P210

46, XX, t(9;22) [20]

CCR

2

M/46

86.5

82.3

12.2

P210

46, XY, t(9;22) [20]

Relapsed

3

M/40

65.3

86.5

8.6

P190

46, XY, t(9;22) [20]

Relapsed

4

M/32

56.6

78.5

10.2

P190

46, XY, t(9;22) [20]

CCR

5

F/50

167.3

98.6

11.6

P190

46, XX, t(9;22) [20]

Relapsed

6

M/22

78.2

92.3

9.8

P190

46, XY, t(9;22) [20]

Relapsed

  1. F, female; M, male; CCR, continuous complete remission